NewLimit Secures $45 Million Funding for Longevity Breakthrough
Longevity research company NewLimit has raised $45 million in new funding to support its mission of reversing cellular ageing. The round includes Lilly Ventures, Duke University, Section 32, and Abstract, with participation from existing investors such as Kleiner Perkins, Dimension, Human Capital, and Boost VC.
The funding values NewLimit at $1.62 billion and comes just five months after its Series B round. According to the company, the raise was driven by recent breakthroughs in its work to restore youthful liver function through advanced epigenetic reprogramming.
Co-founder Jacob Kimmel shared on social media that these developments have given NewLimit “the confidence to start planning clinical studies in the next few years.”
Building the Future of Longevity Medicine
NewLimit, co-founded by Coinbase CEO Brian Armstrong, aims to develop epigenetic therapies that restore youthful cell function. Its approach targets the biological processes that cause ageing at the cellular level.
By reprogramming aged cells, NewLimit hopes to reverse functional decline in human tissues, addressing the root causes of age-related disease rather than treating symptoms.
The company said that the fresh funding will help move its lead program on liver regeneration closer to clinical validation. This program focuses on restoring youthful activity in liver cells — a critical step toward building regenerative treatments for ageing organs.
“Since our Series B, we’ve seen remarkable progress in our lead programs,” NewLimit stated. “These advances give us confidence to begin planning for human studies in the near term.”
Backing from Deep Science Investors
The new round reflects strong backing from both established investors and academic institutions. Lilly Ventures, Duke University, Section 32, and Abstract joined as new capital partners.
Existing investors Kleiner Perkins, Dimension, Human Capital, and Boost VC also increased their commitments, signalling continued belief in NewLimit’s mission.
According to industry observers, this mix of biotech, venture capital, and academic investors suggests growing confidence in longevity medicine as a viable commercial field.
More News: Metya Secures $6 Million to Expand AI Social PayFi Ecosystem
A Step Toward Clinical Validation
NewLimit’s latest breakthrough focuses on restoring youthful liver function, a major challenge in regenerative medicine. The company’s epigenetic reprogramming techniques aim to rejuvenate old cells without altering their genetic code, maintaining safety while renewing biological performance.
The firm said this success “sets the stage for our first clinical study in the coming years.” Clinical translation would mark a significant step in proving that ageing can be slowed or reversed safely in humans.
Longevity researchers view this as a landmark effort — one that may bridge early-stage cellular discoveries with practical medical therapies.
Expanding the Vision of Longevity
NewLimit believes longevity medicine could transform global healthcare. Its goal is to develop therapies that extend healthy lifespan, not merely increase years lived.
In its statement, the company said, “We are firm believers that a new class of longevity medicines can improve lives everywhere, even for those not diagnosed with disease.”
By tackling the epigenetic drivers of ageing, NewLimit hopes to reduce age-related decline, from organ failure to metabolic dysfunction. Its research could redefine how medicine treats ageing — not as an inevitable process, but as a modifiable condition.
A Growing Market for Ageing Science
The longevity sector has seen rising investor interest in 2024 and 2025, with major funds backing startups in cellular rejuvenation, AI-driven drug discovery, and biotech platform innovation.
Experts point to NewLimit’s valuation and scientific progress as a sign that the field is maturing from theory to application. If successful, epigenetic reprogramming could open a new era in preventive medicine, where restoring youthful cell function becomes as common as treating disease.
With $45 million in new capital and a $1.62 billion cap, NewLimit is now one of the best-funded companies in longevity science. The next phase is moving toward clinical trials. Here, they will test both their technology and the promise of age reversal as a medical reality.
To stay updated on crypto venture capital funding and market trends, visit our venture capital news section for more insights.
